Table 1 Top 3 drugs indicated by personalized medicine analysis for MPNST and neurofibroma samples
Sample | Drug 1 | Related transcripts | Drug 2 | Related transcripts | Drug 3 | Related transcripts |
|---|---|---|---|---|---|---|
MPNST-derived cell lines | ||||||
NF02.2 | vorinostat | HDAC1-4, 6 | teniposide | TOP2A | sirolimus | MTOR, FKBP1A |
NF94.3 | pravastatin | MMP2, MMP14, TIMP2 | flavoxate | CHRM2 | sildenafil | PDE5A |
NF96.2 | vorinostat | HDAC1,2, 6 | chlorpromazine | HTR7, DRD2, | dasatinib | ABL1, FYN, KIT |
MPNST samples | ||||||
AS10 | pazopanib | KDR, FLT1, PDGFRB | sorafenib | KDR, FLT1, PDGFRB | sunitinib | KDR, FLT1, PDGFRB |
AS13 | teniposide | TOP2A | etoposide | TOP2A | doxorubicin | TOP2A |
AS15 | teniposide | TOP2A | vorinostat | HDAC2 | sunitinib | KDR, CSF1R |
AS37 | doxycycline | MMP9, MMP13 | pravastatin | MMP9, MMP13 | vorinostat | HDAC2,3,4 |
AS42 | octreotide | SSTR2 | doxycycline | MMP9, MMP13 | pravastatin | MMP9, MMP14 |
AS45 | teniposide | TOP2A | octreotide | SSTR2 | vorinostat | HDAC2,3 |
Benign neurofibroma samples | ||||||
MS37T | dasatinib | EPHA2,KIT | nilotinib | KIT | pazopanib | KIT,KDR |
MS90T | biperiden | CHRM1 | carbinoxamine | CHRM1 | clozapine | CHRM1 |
MS135T | dasatinib | EPHA2 | sorafenib | KIT | pazopanib | KIT,KDR |
MS142T | fluticasone | PGR | medroxyprogesterone | PGR | sorafenib | FLT3 |
MS153T | dasatinib | EPHA2,KIT,LCK,SRC | imatinib | KIT | nilotinib | KIT |
MS156T | sorafenib | KIT | sunitinib | FLT3 | clofarabine | POLA1 |